FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/ chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies.
No abstract available
References:
Chan O, Renneville A, Padron E. Chronic myelomonocytic leukemia diagnosis and management. Leukemia. 2021;35(6):1552-1562.
Sekeres MA, Taylor J. Diagnosis and treatment of myelodysplastic syndromes: a review. JAMA. 2022;328(9):872-880.
Peterlin P, Le Bris Y, Turlure P, et al. . CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Haematol. 2023;10(7):e521-e529.
Peterlin P, Gaschet J, Guillaume T, et al. . A new cytokine-based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia. Cancer Med. 2021;10(2):642-648.
Peterlin P, Gaschet J, Bertoli S, et al. . Fms-like tyrosine kinase 3 Ligand kinetic profile is the strongest factor predicting refractoriness after induction and event-free survival in adults with AML: a Filo prospective multicentric study. Blood. 2023;142(Suppl 1):975.